Shirai Y, Ohtani T, Tsukada K, Hatakeyama K
Department of Surgery, Niigata University School of Medicine, Niigata City, Japan.
Cancer. 1997 Nov 15;80(10):1904-9.
The objective of this study was to evaluate the efficacy of combined pancreaticoduodenectomy and hepatectomy for the treatment of patients with locally advanced gallbladder carcinoma.
Long term results over 5 years of follow-up were analyzed retrospectively in 17 consecutive patients with gallbladder carcinoma who underwent combined pancreaticoduodenectomy and hepatectomy with radical lymphadenectomy. The indications for pancreaticoduodenectomy were direct invasion of the adjacent organs (stomach, duodenum, or pancreas) and/or the presence of peripancreatic (head only) lymph node metastases. The hepatectomy performed was a nonanatomic resection of the gallbladder bed in 15 patients and an extended right hepatectomy in 2 patients. There was 1 in-hospital death (6%).
Overall, 5 patients (29%) survived 5 years after surgery. Of these patients, four had Stage IVB disease with positive peripancreatic lymph nodes. Eight of the 10 patients who underwent a potentially curative resection survived longer than 3 years, whereas none of the 7 patients with residual tumor survived beyond 15 months. The 5-year survival of 50% (median survival: 58.5 months) in those undergoing a potentially curative resection was significantly better than the 5-year survival of 0% (median survival: 8 months) observed in those patients with residual tumor (P = 0.00086).
Combined pancreaticoduodenectomy and hepatectomy is an efficacious treatment for patients with locally advanced gallbladder carcinoma, but only if a potentially curative resection is feasible. The presence of peripancreatic (head only) lymph node disease is not a contraindication for this procedure.
本研究的目的是评估胰十二指肠切除术联合肝切除术治疗局部晚期胆囊癌患者的疗效。
回顾性分析17例连续接受胰十二指肠切除术联合肝切除术及根治性淋巴结清扫术的胆囊癌患者超过5年的长期随访结果。胰十二指肠切除术的指征为相邻器官(胃、十二指肠或胰腺)的直接侵犯和/或胰周(仅头部)淋巴结转移。15例行胆囊床非解剖性切除,2例行扩大右肝切除术。有1例院内死亡(6%)。
总体而言,5例患者(29%)术后存活5年。其中,4例为IVB期疾病,胰周淋巴结阳性。10例接受潜在根治性切除的患者中有8例存活超过3年,而7例有残留肿瘤的患者无一存活超过15个月。接受潜在根治性切除的患者5年生存率为50%(中位生存期:58.5个月),显著优于有残留肿瘤患者的5年生存率0%(中位生存期:8个月)(P = 0.00086)。
胰十二指肠切除术联合肝切除术是治疗局部晚期胆囊癌患者的有效方法,但前提是潜在根治性切除可行。胰周(仅头部)淋巴结疾病的存在并非该手术的禁忌证。